Search results
Showing 7996 to 8010 of 8245 results
NICE announces proposals to transform its HealthTech programme to drive more technology into the NHS
Consultation launches on the biggest shake-up of NICE's HealthTech programme to date.
Consultation on changes to technology appraisals and highly specialised technologies
Home What NICE does Our guidance About technology appraisal guidance Our methods and processes (health technology evaluation manual) Methods and...
Healthcare professionals advised to ask people about gambling at health checks and GP appointments
The recommendation is included in our first clinical guideline on gambling-related harms: identification, assessment and management.
Thousands of people with a severe dust mite allergy are set to benefit from life-changing treatment
We've recommended an innovative daily tablet treatment shown to reduce symptoms and improve quality of life.
We have also recommended osimertinib for routine use on the NHS today.
Recommendations will help organisations that evaluate new drugs establish whether their use will result in longer-term benefits for patients
Learn more about the proposed changes to our routing criteria for highly specialised technologies
Home News Podcasts Learn more about the proposed changes to our routing criteria for highly specialised technologies Podcasts 31 December 2024
NICE describes how weight loss drug tirzepatide will be rolled out
The medication will initially be offered only to those people with the highest clinical needs.
NICE recommends new treatment to prevent and reduce hearing loss in people being treated for cancer
For the first time, NICE has recommended an innovative new treatment to help stop babies, children and young people who are undergoing cancer treatment from losing their hearing.
Over 1000 people with advanced breast cancer set to benefit from new once-a-day tablet
We’ve issued final draft guidance recommending a new once-a-day tablet that is set to benefit around 1,100 people with a type of advanced breast cancer.
Public consultation launched on changes to NICE's Highly Specialised Technologies routing criteria
NICE is proposing changes to its routing criteria for Highly Specialised Technologies (HST) to ensure more consistent, predictable and transparent decisions.
An insight into one of NICE’s most long-standing collaborative relationships.
NICE recommends Piqray and Trodelvy, maintaining 100% approvals of breast cancer drugs since 2018.
Tributes paid following the death of founding NICE chairman Professor Sir Mike Rawlins
Founding chairman led NICE from 1999 to 2013, through its early years to its current position as a world leader in health and social care guidance and medicine evaluation.
NICE recommends Enhertu for more people with advanced breast cancer
Hundreds more people eligible for breast cancer drug Enhertu as NICE recommends it for earlier stage disease, in final draft guidance.